Taysha Gene Therapies Inc (TSHA)

Aug 11, 2026, 4:30 PM EDT - 7 days ago

Taysha Gene Therapies Earnings Call Transcript: Q2 2026

Aug 11, 2026, 4:30 PM EDT - 7 days ago

Taysha Gene Therapies Earnings release: Q2 2026

Aug 11, 2026, 4:30 PM EDT - 7 days ago

Taysha Gene Therapies Quarterly report: Q2 2026

2026-08-11T20:06:15.000Z - 7 days ago

Taysha Gene Therapies reports Q2 EPS (13c), consensus (11c)

Aug 11, 2026, 4:00 PM EDT - 7 days ago

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 7, 2026, 8:00 AM EDT - 12 days ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 4, 2026, 4:00 PM EDT - 14 days ago

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

2026-08-03T12:20:35.000Z - 16 days ago

Taysha Gene Therapies, Catalent announce commercial supply pact for TSHA-102

Aug 3, 2026, 8:00 AM EDT - 16 days ago

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

2026-07-21T09:55:44.000Z - 4 weeks ago

Taysha Gene Therapies price target raised to $13 from $11 at Goldman Sachs

2026-07-13T16:05:18.000Z - 5 weeks ago

Taysha Gene Therapies falls -11.0%

Jul 1, 2026, 8:00 AM EDT - 7 weeks ago

Taysha Gene Therapies Slides: Corporate presentation

2026-06-30T11:10:21.000Z - 7 weeks ago

Taysha Gene Therapies price target raised to $15 from $12 at Baird

Jun 25, 2026, 4:01 PM EDT - 7 weeks ago

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

2026-06-25T19:50:09.000Z - 7 weeks ago

Taysha Gene Therapies management to meet with Piper Sandler

2026-06-25T03:30:10.000Z - 7 weeks ago

Taysha Gene Therapies 32.5M share Spot Secondary priced at $6.00

Jun 24, 2026, 10:33 PM EDT - 7 weeks ago

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

2026-06-24T20:05:37.000Z - 7 weeks ago

Taysha Gene Therapies announces $200M common stock offering

Jun 24, 2026, 4:01 PM EDT - 7 weeks ago

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-06-23T15:52:22.000Z - 2 months ago

Taysha Gene Therapies price target raised to $14 from $10 at BMO Capital

2026-06-23T15:50:32.000Z - 2 months ago

Taysha Gene Therapies price target raised to $14 from $10 at BMO Capital

2026-06-23T11:34:45.000Z - 2 months ago

Taysha Gene Therapies price target raised to $10 from $9 at BofA

2026-06-23T09:46:55.000Z - 2 months ago

Taysha Gene Therapies price target raised to $11 from $8 at Citizens

Jun 22, 2026, 8:30 AM EDT - 2 months ago

Taysha Gene Therapies Transcript: Study result

Jun 22, 2026, 8:30 AM EDT - 2 months ago

Taysha Gene Therapies Press release: Study result

Jun 22, 2026, 8:30 AM EDT - 2 months ago

Taysha Gene Therapies Slides: Study result

2026-06-22T12:22:21.000Z - 2 months ago

Taysha Gene Therapies completes dosing in REVEAL pivotal trial

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

Jun 1, 2026, 9:00 AM EDT - 2 months ago

Taysha Gene Therapies Transcript: AGM 2026

2026-05-07T05:59:38.000Z - 3 months ago

Taysha Gene Therapies reports Q1 EPS (12c), consensus (10c)

May 6, 2026, 8:30 AM EDT - 3 months ago

Taysha Gene Therapies Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

Taysha Gene Therapies Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

Taysha Gene Therapies Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Apr 27, 2026, 5:21 PM EDT - 4 months ago

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Taysha Gene Therapies Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Taysha Gene Therapies Proxy statement: Proxy filing

2026-04-06T11:09:44.000Z - 4 months ago

Taysha Gene Therapies price target raised to $17 from $14 at Canaccord

Mar 19, 2026, 8:30 AM EDT - 5 months ago

Taysha Gene Therapies Earnings Call Transcript: Q4 2025

Mar 19, 2026, 8:30 AM EDT - 5 months ago

Taysha Gene Therapies Annual report: Q4 2025

Mar 19, 2026, 8:30 AM EDT - 5 months ago

Taysha Gene Therapies Earnings release: Q4 2025

2026-03-19T12:11:24.000Z - 5 months ago

Taysha Gene Therapies reports 2025 EPS (34c), consensus (34c)

Mar 19, 2026, 8:00 AM EDT - 5 months ago

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

Jan 22, 2026, 10:26 AM EST - 7 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 6, 2026, 8:00 AM EST - 8 months ago

Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

Nov 4, 2025, 8:30 AM EST - 10 months ago

Taysha Gene Therapies Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Taysha Gene Therapies Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Taysha Gene Therapies Quarterly report: Q3 2025

Nov 4, 2025, 7:00 AM EST - 10 months ago

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

Oct 16, 2025, 4:01 PM EDT - 10 months ago

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

Oct 9, 2025, 8:00 AM EDT - 11 months ago

Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting

Oct 2, 2025, 8:00 AM EDT - 11 months ago

Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Taysha Gene Therapies Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Taysha Gene Therapies Quarterly report: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Taysha Gene Therapies Earnings release: Q2 2025

Aug 12, 2025, 8:01 AM EDT - 1 year ago

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 4:05 PM EDT - 1 year ago

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12

Jun 3, 2025, 5:17 PM EDT - 1 year ago

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

May 28, 2025, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

May 15, 2025, 8:30 AM EDT - 1 year ago

Taysha Gene Therapies Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Taysha Gene Therapies Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Taysha Gene Therapies Earnings release: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Proxy statement: Proxy Filing

May 8, 2025, 4:05 PM EDT - 1 year ago

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Proxy statement: Proxy Filing

Mar 31, 2025, 2:25 PM EDT - 1 year ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SLDB SRPT XBI

Feb 26, 2025, 8:30 AM EST - 1 year ago

Taysha Gene Therapies Earnings Call Transcript: Q4 2024

Feb 26, 2025, 8:30 AM EST - 1 year ago

Taysha Gene Therapies Annual report: Q4 2024

Feb 26, 2025, 8:30 AM EST - 1 year ago

Taysha Gene Therapies Earnings release: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Feb 19, 2025, 8:00 AM EST - 1 year ago

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

Dec 13, 2024, 7:00 AM EST - 1 year ago

Taysha Gene Therapies Registration statement: Registration Filing

Nov 13, 2024, 4:30 PM EST - 1 year ago

Taysha Gene Therapies Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Taysha Gene Therapies Quarterly report: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Taysha Gene Therapies Earnings release: Q3 2024

Nov 13, 2024, 4:01 PM EST - 1 year ago

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Taysha Gene Therapies Earnings Call Transcript: Q2 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Taysha Gene Therapies Quarterly report: Q2 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Taysha Gene Therapies Earnings release: Q2 2024

Aug 12, 2024, 8:01 AM EDT - 2 years ago

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Transcript: Status Update

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Press release: Status Update

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Slides: Status Update

Jun 18, 2024, 7:30 AM EDT - 2 years ago

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Jun 12, 2024, 7:00 AM EDT - 2 years ago

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

May 14, 2024, 4:30 PM EDT - 2 years ago

Taysha Gene Therapies Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Taysha Gene Therapies Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Taysha Gene Therapies Earnings release: Q1 2024

May 14, 2024, 4:01 PM EDT - 2 years ago

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 4:05 PM EDT - 2 years ago

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

May 2, 2024, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Taysha Gene Therapies Proxy statement: Proxy Filing

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Taysha Gene Therapies Earnings Call Transcript: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Taysha Gene Therapies Annual report: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Taysha Gene Therapies Earnings release: Q4 2023

Mar 19, 2024, 4:01 PM EDT - 2 years ago

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Mar 14, 2024, 4:26 PM EDT - 2 years ago

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

Feb 29, 2024, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

Feb 15, 2024, 4:01 PM EST - 2 years ago

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Jan 22, 2024, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

Jan 10, 2024, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Dec 19, 2023, 7:30 AM EST - 2 years ago

Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies

TRIN

Nov 29, 2023, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Nov 14, 2023, 4:30 PM EST - 3 years ago

Taysha Gene Therapies Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Taysha Gene Therapies Quarterly report: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Taysha Gene Therapies Earnings release: Q3 2023

Nov 14, 2023, 4:08 PM EST - 3 years ago

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 7, 2023, 8:00 AM EST - 3 years ago

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

Oct 24, 2023, 8:00 AM EDT - 3 years ago

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Oct 10, 2023, 8:00 AM EDT - 3 years ago

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress